Presenting Pivotal Phase 3 Sickle Cell Data at EHA 2026- Agios Pharmaceuticals
Agios Pharmaceuticals shared a post on LinkedIn:
“Agios News: Today, during the Plenary Abstracts Session at EHA 2026, we presented detailed results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.
This oral presentation included new transfusion burden and hemoglobin responder analyses that reinforce the strong anti-hemolytic profile of our first-in-class PK activator.
Read the results.”
Mohamed A., Franchise Director, Blood Disorders, Rare Disease GCC at NewBridge Pharmaceuticals, shared this post on LinkedIn:
“Results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 4, 2026, 21:28New Frontiers in Platelet Biology – BJHaem
-
Aug 4, 2026, 20:48New Real-World Data on Efanesoctocog Alfa From France – CRH French Reference Center for Hemophilia Lyon
-
Aug 4, 2026, 20:37Hisam Siddiqi: Haemoglobinopathy Basics – A Quick Guide to Thalassaemia
-
Aug 4, 2026, 20:36Ifeanyichukwu Ifechidere: AI May Soon Interpret Coagulation Results Better Than Some Healthcare Professionals
-
Aug 4, 2026, 20:35Ediga Naga Pradeep Kumar: Excited to Share My Latest Data Analytics Project – Stroke Risk Analysis Dashboard
-
Aug 4, 2026, 20:34Amar Shah: Improving Thrombolysis for Acute Stroke Through Quality Improvement
-
Aug 4, 2026, 20:33Federica Sepe: Are Biomarkers Finally Ready for Precision Stroke Medicine?
-
Aug 4, 2026, 20:10Kabir Olaniran: Sickle Cell Trait and Chronic Kidney Disease Risk
-
Aug 4, 2026, 19:57Toby Richards: Iron Deficiency Beyond Anaemia in Female Triathletes